

LJMU Research Online

Wagmann, L, Richter, LHJ, Kehl, T, Wack, F, Pettersson Bergstrand, M, Brandt, SD, Stratford, A, Maurer, HH and Meyer, MR

In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures

http://researchonline.ljmu.ac.uk/id/eprint/9841/

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Wagmann, L, Richter, LHJ, Kehl, T, Wack, F, Pettersson Bergstrand, M, Brandt, SD, Stratford, A, Maurer, HH and Meyer, MR (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Analytical and

LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@limu.ac.uk

Analytical and Bioanalytical Chemistry

Electronic Supplementary Material

In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures

Lea Wagmann, Lilian H. J. Richter, Tobias Kehl, Franziska Wack, Madeleine Pettersson Bergstrand, Simon D. Brandt, Alexander Stratford, Hans H. Maurer, and Markus R. Meyer




Fig. S1: HRMS/MS spectra of LSD-based new psychoactive substances and their most abundant, unique metabolites along with their retention times (RT). Numbering according to Table 1 in the manuscript.




Fig. S1 (continued)




Fig. S1 (continued)




Fig. S1 (continued)




Fig. S2: Metabolic pathways of LSD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.

Fig. S3: Metabolic pathways of ALD-52 studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S4: Metabolic pathways of 1B-LSD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S5: Metabolic pathways of ETH-LAD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.

Fig. S6: Metabolic pathways of 1P-ETH-LAD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.

Fig. S7: Metabolic pathways of AL-LAD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S8: Metabolic pathways of ECPLA studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S9: Metabolic pathways of LSZ studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.




Fig. S10: Metabolic pathways of LSM-775 studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.